Small business owners across the United States are facing a significant financial hurdle as health insurers propose a median premium increase of 14% for the 2027 plan year. This projection, detailed in a comprehensive analysis by KFF (formerly the Kaiser Family Foundation) and the Peterson Center on Healthcare, underscores a period of accelerating healthcare costs that threatens the viability of employer-sponsored coverage for millions of American workers. The report, which scrutinized 295 rate filings from Affordable Care Act (ACA)-compliant small group insurers across all 50 states and the District of Columbia, reveals a market under intense pressure from rising pharmaceutical spending, regulatory shifts, and a changing risk pool.
The small group insurance market, which primarily serves businesses with 50 or fewer employees, has historically been a cornerstone of the American workforce’s social safety net. However, the 2027 filings suggest that the era of modest, single-digit premium hikes may be coming to an end. According to the data, nearly 60% of insurers in this segment are seeking increases ranging between 10% and 20%. Perhaps more concerning for small enterprises is the fact that 15% of insurers are requesting hikes exceeding 20%, a level of volatility that often forces businesses to reduce benefits, increase employee cost-sharing, or drop coverage entirely.
The Primary Catalyst: Escalating Medical and Pharmacy Trends
The fundamental driver behind the 2027 premium surge is the underlying cost of providing medical care. In the filings reviewed—specifically those from 14 states and D.C. where detailed, unredacted data was available—insurers cited a median expected increase in medical costs of 10.8%. This figure represents a blend of "unit price" increases (the amount providers charge for services) and "utilization" (the frequency with which members seek care).
A major component of this trend is the unprecedented growth in spending on specialty pharmaceuticals. Insurers have specifically pointed to the rising prevalence and cost of GLP-1 medications, such as those used for diabetes and weight loss. While these drugs offer significant clinical benefits, their high price tags and long-term usage requirements are straining the budgets of small group plans. Unlike larger corporations that may have the scale to negotiate deeper rebates with pharmacy benefit managers, small group plans often feel the full weight of these price increases.
Furthermore, the lack of generic alternatives for many high-cost specialty drugs means there is little relief in sight. Beyond weight-loss medications, insurers noted increased spending on gene therapies and complex biologics. The report highlights that as these treatments become more common, their impact on the small group market is magnified because the cost is spread over a relatively small number of enrollees.
Mental Health and Substance Use Disorder Utilization
The post-pandemic landscape has seen a sustained increase in the demand for mental health services and substance use disorder (SUD) treatment. Insurers noted that both the volume of claims and the cost per claim for these services have risen significantly. This trend is driven by several factors, including a broader cultural shift toward seeking mental healthcare, the long-term psychological impacts of the COVID-19 pandemic, and federal mental health parity requirements that mandate insurers provide coverage for mental health services that is no more restrictive than coverage for medical or surgical care.
While these services are essential for public health, the rapid growth in utilization has outpaced previous actuarial projections. Insurers in states like Massachusetts and New York have specifically called out mental health spending as a primary factor necessitating their 2027 rate requests, noting that the "spend" in this category is growing at its fastest rate in over a decade.
Regulatory Pressures and the No Surprises Act
An unexpected contributor to rising premiums identified in the KFF-Peterson analysis is the impact of the No Surprises Act. Enacted to protect patients from unexpected out-of-network medical bills, the law established an Independent Dispute Resolution (IDR) process to settle payment disagreements between insurers and providers.
However, insurers argue that the implementation of this process has led to unintended financial consequences. Filings indicate that healthcare providers have initiated a much higher volume of disputes than initially anticipated. More importantly, insurers claim that providers are winning a vast majority of these cases at award levels that are significantly higher than typical in-network rates. This "inflationary" effect on reimbursement rates is being passed directly to employers and employees through higher premiums. The IDR process, while successful in protecting consumers from "balance billing," has created a new baseline for provider compensation that insurers say is unsustainable without corresponding premium increases.
The Shrinking Pool: Enrollment Declines and Adverse Selection
One of the most systemic challenges facing the small group market is the ongoing decline in total enrollment. As premiums rise, a phenomenon known as "adverse selection" begins to take hold. Healthier small businesses, whose employees have lower medical needs, are increasingly seeking alternatives to the fully insured ACA-compliant market.
These alternatives often include "level-funded" plans or Individual Coverage Health Reimbursement Arrangements (ICHRAs). Level-funded plans allow small businesses to enjoy some of the benefits of self-insurance, including the potential for refunds if claims are low, while ICHRAs allow employers to provide tax-free funds for employees to buy their own insurance on the individual exchange.
As healthier groups exit the traditional small group market, the remaining "pool" of insured individuals becomes sicker on average. This necessitates higher premiums to cover the higher per-capita costs, which in turn drives more healthy groups away—a cycle often referred to by economists as a "death spiral." Moda Health Plan in Oregon noted in its filing that the decrease in overall enrollment signifies that lower-cost groups are finding more favorable rates elsewhere, leaving behind a sicker, more expensive population to insure.
Regional Variations and State-Level Data
The KFF-Peterson analysis drew heavily from unredacted filings in 14 states, including Connecticut, Hawaii, Illinois, Kansas, Michigan, and Vermont. While the median increase is 14%, the regional data shows a wide spectrum of proposed changes. For example:
- Massachusetts: Blue Cross and Blue Shield of Massachusetts HMO Blue noted that healthcare spending is growing at the fastest rate in more than ten years, citing both price inflation and high-intensity service utilization.
- Oregon: Insurers expressed concern over the "churn" of enrollment and the migration of small businesses toward alternative funding models.
- Vermont and Maine: These states, which often have smaller, older populations, are seeing some of the highest requested increases as insurers struggle to manage the costs of a high-utilization demographic.
The disparity in rate filings suggests that while national trends like drug costs are universal, local provider market consolidation and state-specific regulations also play a critical role in determining what a small business pays for coverage.
Economic Implications for Small Businesses
For the millions of Americans employed by small businesses, these premium hikes represent a direct threat to their total compensation and financial stability. Small business owners operate on thinner margins than their larger counterparts and have less leverage to absorb a 14% increase in one of their largest fixed costs.
Historically, when faced with double-digit premium increases, small employers have reacted in several ways:
- Cost Shifting: Increasing the percentage of the premium paid by the employee or raising deductibles and out-of-pocket maximums.
- Wage Stagnation: Redirecting funds that might have gone toward annual raises to cover the increased cost of health benefits.
- Reducing Benefits: Opting for "skinny" plans that cover fewer services or have more restrictive provider networks.
- Dropping Coverage: In extreme cases, businesses may cease offering health insurance altogether, directing employees to the individual ACA marketplace, potentially with an ICHRA contribution.
The 2027 projections suggest that more businesses will be forced into these difficult decisions, potentially leading to a fragmentation of the employer-sponsored insurance system that has defined the American workplace since World War II.
Looking Ahead: 2027 and Beyond
The 14% median increase proposed for 2027 is a "canary in the coal mine" for the broader healthcare economy. It reflects a convergence of high-cost innovation (GLP-1s), regulatory friction (No Surprises Act), and structural market shifts (enrollment declines). While state regulators have the authority to review and potentially lower these requested rates, the underlying cost drivers remain largely outside their control.
Policy analysts suggest that without significant intervention—either in the form of pharmaceutical price transparency, reforms to the IDR process, or incentives to keep healthy groups in the small group pool—the trend of aggressive premium hikes is likely to persist. For now, small businesses and their employees must prepare for a 2027 where the cost of staying healthy requires a significantly larger share of the company budget. The KFF and Peterson Center report serves as a stark reminder that the "inflation" conversation in healthcare is far from over, and its most acute impact may be felt by the nation’s smallest employers.
